当前蛋白身份:Q16548 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
2VM6 Human Bcl2-A1 in complex with Bim-BH3 peptide 提交 2008-01-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–149(149 aa) 片段:RESIDUES 1-149
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.8;293 K;0.1M BIS, TRIS PH 5.8, 2M AMSO4
分辨率 2.20 Å R-free 0.250
3I1H Crystal structure of human BFL-1 in complex with BAK BH3 peptide 提交 2009-06-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa) 片段:residues 1-151
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.8;298 K;1.5 M sodium malonate, pH 5.8 protein 1.67 mg/ml, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.20 Å R-free 0.238
3MQP Crystal Structure of human BFL-1 in complex with NOXA BH3 peptide, Northeast Structural Genomics Consortium Target HR2930 提交 2010-04-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4.4;296 K;Protein solution: 100mM NaCl, 5mM DTT, 0.02% NaN3, 10mM Tris-HCl (pH 7.5) . Reservoir solution: 1.5 M Sodium Malonate, 0.1 M sodium Acetate, VAPOR DIFFUSION, HANGING DROP, temperature 296K
分辨率 2.24 Å R-free 0.230
4ZEQ Crystal Structure of human BFL-1 in complex with tBid BH3 peptide, Northeast Structural Genomics Consortium Target HX9247 提交 2015-04-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.4;295 K;Sodium Malonate
分辨率 1.80 Å R-free 0.239
5UUK Human Bfl-1 in complex with a Bfl-1-specific selected peptide 提交 2017-02-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa) 片段:UNP residues 1-151
未记录 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 7.0
分辨率 1.20 Å R-free 0.163
5UUL Human Bfl-1 in complex with PUMA BH3 提交 2017-02-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa) 片段:UNP residues 1-151
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 7.0
分辨率 1.33 Å R-free 0.155
5UUP Human Bfl-1 covalently cross-linked to an electrophilic variant of a Bfl-1-specific selected peptide 提交 2017-02-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa) 片段:UNP residues 1-151
未记录 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 7.0
分辨率 1.73 Å R-free 0.206
5WHH Crystal Structure of Bcl-2-related protein A1 in complex with stapled peptide (AQ7)T(0EH)LRRFGD(MK8)INFRQ(NH2) 提交 2017-07-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
突变:C4S, C19S CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;298 K;PEG3350 20%, 0.2M Sodium malonate
分辨率 2.38 Å R-free 0.293
5WHI Crystal Structure of Bcl-2-related protein A1 提交 2017-07-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa) 片段:BFL1
突变:C4S, C19S CAD CACODYLIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;298 K;PEG2000
分辨率 1.69 Å R-free 0.233
6E3I Human Bfl-1 in complex with the Bfl-1-specific designed peptide srt.F4 提交 2018-07-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 7.0
分辨率 1.48 Å R-free 0.173
6E3J Human Bfl-1 in complex with the Bfl-1-specific designed peptide srt.F10 提交 2018-07-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 7.0
分辨率 1.48 Å R-free 0.178
6MBB Human Bfl-1 in complex with the designed peptide dF1 提交 2018-08-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;298 K;1.8 M ammonium sulfate, 0.1 M MES pH 6.5
分辨率 1.59 Å R-free 0.196
6MBC Human Bfl-1 in complex with the designed peptide dF4 提交 2018-08-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–151(151 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;295 K;1.8 - 2.0 M NH4SO4, 50 mM MES pH 6.5
分辨率 1.75 Å R-free 0.212
6RJP Bfl-1 in complex with alpha helical peptide 提交 2019-04-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–149(149 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 EVAPORATION;293 K;0.1 M sodium acetate pH 4.6 16% (w/v) PEG smear high
分辨率 2.57 Å R-free 0.266
6RJP Bfl-1 in complex with alpha helical peptide 提交 2019-04-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–149(149 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 EVAPORATION;293 K;0.1 M sodium acetate pH 4.6 16% (w/v) PEG smear high
分辨率 2.57 Å R-free 0.266
6VO4 Crystal Structure Analysis of BFL1 提交 2020-01-29 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;3.5M Sodium formate, pH 7.0
分辨率 1.74 Å R-free 0.283
8RPO BFL1 in complex with a reversible covalent ligand 提交 2024-01-16 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1H2C (~{E})-2-cyano-3-(2-dimethylphosphorylphenyl)-~{N}-[[1-[4-(trifluoromethyl)phenyl]cyclopropyl]methyl]prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6;293 K;sodium citrate 0.3M, PCTP pH 6
分辨率 1.79 Å R-free 0.262
9EW8 Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-04-03 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1H7Q 1-[(2R)-2-phenylpyrrolidin-1-yl]propan-1-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.85M sodium citrate, 0.1M PCTP pH 6
分辨率 1.49 Å R-free 0.271
9FKY Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-06-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1IDP ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-[3-cyano-4-(trifluoromethyl)phenyl]ethyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;310 K;PCPT 0.1M pH 5, Na3 Cit 1.1M
分辨率 1.56 Å R-free 0.237
9FKY Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-06-04 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–151(151 aa)
未记录 A1IDP ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-[3-cyano-4-(trifluoromethyl)phenyl]ethyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;310 K;PCPT 0.1M pH 5, Na3 Cit 1.1M
分辨率 1.56 Å R-free 0.237
9FKZ Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-06-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1IDO ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(4-chlorophenyl)methyl]prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;310 K;Na3 Cit 1M, PCPT 0.1M pH 7
分辨率 1.68 Å R-free 0.339
9FL0 Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-06-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1IDG ~{N}-[(4-chlorophenyl)methyl]-~{N}-(4-fluorophenyl)prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;310 K;PCPT 0.1M pH 7, Na3 Cit 1M
分辨率 1.94 Å R-free 0.281
9FL0 Discovery of a Series of Covalent, Cell Active Bfl-1 Inhibitors 提交 2024-06-04 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–151(151 aa)
未记录 A1IDG ~{N}-[(4-chlorophenyl)methyl]-~{N}-(4-fluorophenyl)prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;310 K;PCPT 0.1M pH 7, Na3 Cit 1M
分辨率 1.94 Å R-free 0.281
9GIP BFL1 covalently bound to inhibitor compound 7 提交 2024-08-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1ILY ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.71;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 8.71, Na3 Citrate 0.93 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.46 Å R-free 0.249
9GIQ BFL1 covalently bound to inhibitor compound 13 提交 2024-08-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 BUD (2S,3S)-butane-2,3-diol × 1 A1ILV ~{N}-[4-[(1~{R},3~{R})-3-azanylcyclopentyl]oxyphenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)-3-methyl-3-oxidanyl-butyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 9.5;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 9.50, Na3 Citrate 0.60 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.42 Å R-free 0.257
9GIR BFL1 covalently bound to inhibitor compound 39 提交 2024-08-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1ILX ~{N}-[4-[(1~{R},3~{R})-3-[[(3~{R})-1,1-bis(oxidanylidene)thiolan-3-yl]carbamoylamino]cyclopentyl]oxy-3-chloranyl-phenyl]-~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.71;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 4.78, Na3 Citrate 0.60 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.07 Å R-free 0.210
9GIS BFL1 covalently bound to inhibitor compound 17 提交 2024-08-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1ILU ~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]-~{N}-[4-[(1~{R},3~{R})-3-[[(3~{S})-pyrrolidin-3-yl]carbamoylamino]cyclopentyl]oxyphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.93;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 7.93, Na3 Citrate 0.60 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.39 Å R-free 0.254
9GIS BFL1 covalently bound to inhibitor compound 17 提交 2024-08-19 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–151(151 aa)
未记录 A1ILU ~{N}-[(1~{S})-1-(4-chlorophenyl)ethyl]-~{N}-[4-[(1~{R},3~{R})-3-[[(3~{S})-pyrrolidin-3-yl]carbamoylamino]cyclopentyl]oxyphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.93;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 7.93, Na3 Citrate 0.60 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.39 Å R-free 0.254
9GIT BFL1 covalently bound to inhibitor compound 43 提交 2024-08-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1ILW (3~{S})-3-[[4-[(1~{R},3~{R})-3-[[(3~{R})-1,1-bis(oxidanylidene)thiolan-3-yl]carbamoylamino]cyclopentyl]oxy-3-fluoranyl-phenyl]-propanoyl-amino]-3-(4-chlorophenyl)propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.14;293 K;Protein:ligand complex at ~4mg/ml in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM TCEP, 1%DMSO. 150nL mixed with 150nL of well solution, 0.1M PCPT* pH 7.14, Na3 Citrate 0.92 M. *PCPT = Sodium propionate, sodium cacodylate trihydrate, bis-tris propane buffer system. Using STPLabtech Mosquito.
分辨率 1.15 Å R-free 0.212
9S6M Structure of BFL1 in complex with a covalent inhibitor, alternative series, cmpd25 提交 2025-08-01 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–151(151 aa)
未记录 A1JL2 (1~{R},2~{R})-2-azanyl-~{N}-[4-[(1~{R})-1-[propanoyl-[4-(trifluoromethyloxy)phenyl]amino]ethyl]phenyl]cyclopentane-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;Crystallization of adducted protein was carried out using a 2D optimization grid, (sodium citrate 0.6-1.1 M, vs PCTP buffer, 0.1 M pH 4.5-9.5). 300 nL drops (150 nL protein, 150 nL mother liquor) were incubated at 293 K in a sitting drop vapour diffusion format, dispensed using a Mosquito (SPT Labtech) and SWISSCI MRC 2-drop plates
分辨率 1.43 Å R-free 0.214
9S6M Structure of BFL1 in complex with a covalent inhibitor, alternative series, cmpd25 提交 2025-08-01 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–151(151 aa)
未记录 A1JL2 (1~{R},2~{R})-2-azanyl-~{N}-[4-[(1~{R})-1-[propanoyl-[4-(trifluoromethyloxy)phenyl]amino]ethyl]phenyl]cyclopentane-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;Crystallization of adducted protein was carried out using a 2D optimization grid, (sodium citrate 0.6-1.1 M, vs PCTP buffer, 0.1 M pH 4.5-9.5). 300 nL drops (150 nL protein, 150 nL mother liquor) were incubated at 293 K in a sitting drop vapour diffusion format, dispensed using a Mosquito (SPT Labtech) and SWISSCI MRC 2-drop plates
分辨率 1.43 Å R-free 0.214